Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Neuroimmune Diseases [[electronic resource] ] : From Cells to the Living Brain / / edited by Hiroshi Mitoma, Mario Manto
| Neuroimmune Diseases [[electronic resource] ] : From Cells to the Living Brain / / edited by Hiroshi Mitoma, Mario Manto |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (819 pages) |
| Disciplina | 616.8 |
| Collana | Contemporary Clinical Neuroscience |
| Soggetto topico |
Neurosciences
Neurology Neurology |
| ISBN | 3-030-19515-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Overview of mechanisms underlying neuroimmune diseases -- 2. Roles of interleukines in neurological autoimmunity -- 3. Roles of regulatory T cells in neurological autoimmunity -- 4.Immune tolerance triggering neurological autoimmunity -- 5. Disruption of blood-brain barrier and blood-nerve barrier: a key step in development of immune-mediated neurological diseases -- 6. Pathological mechanisms underlying production of autoantibodies -- 7. Significance of autoantibodies: cause or result? -- 8. Multiple actions of microglia -- 9. Autoimmune astropathy -- 10. Genetic factors indicating susceptibility to neurological diseases -- 11. General principles of immunotherapy -- 12. Multiple sclerosis -- 13. Neuromyelitis optica: Diagnosis and therapies -- 14. Atypical inflammatory demyelinating syndrome -- 15. Central nervous system vasculitis -- 16. Neuro-Beçhet and Sjőgren disease -- 17. Immune-mediated cortical encephalopathy (Limbic encephalitis) -- 18. Immune-mediated cerebellar ataxias -- 19. Stiff-Person syndrome -- 20. Guillain-Barré syndrome -- 21. Chronic inflammatory demyelinating polyneuropathy: Diagnosis and therapy -- 22. Immune-mediated disorders of neuro-muscular junctions -- 23. Myositis -- 24. Infection-related immune diseases -- 25. Paraneoplastic neurological syndromes; Diagnosis and Therapies. |
| Record Nr. | UNINA-9910349449803321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
New rapid-acting Antidepressants / / edited by Kenji Hashimoto and Mario Manto
| New rapid-acting Antidepressants / / edited by Kenji Hashimoto and Mario Manto |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (152 pages) |
| Disciplina | 616.8527061 |
| Collana | Contemporary Clinical Neuroscience |
| Soggetto topico |
Neurosciences
Antidepressants Antidepressius |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-79790-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- (R)-Ketamine: A New Rapid-Acting Antidepressant -- Rapid-Acting Antidepressant Ketamine -- What Is (R)-Ketamine? -- (R)-Ketamine's Antidepressant Effects -- Gender Differences -- (R)-Ketamine and its Final Metabolite, (2R,6R)-Hydroxynorketamine -- Side Effects -- Potential Mechanisms of Ketamine's Antidepressant Actions -- 5-Hydroxytryptamine -- α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor Activation -- Dopamine -- Opioid System -- γ-Aminobutyric Acid -- Inflammatory Bone Markers -- ERK -- Gut Microbiota -- Conclusion -- References -- (2R,6R)-Hydroxynorketamine, A Metabolite of Ketamine: The Antidepressant Actions and the Mechanisms -- Introduction -- Antidepressant-like Actions of (2R,6R)-Hydroxynorketamine -- Brain Regions for the Antidepressant-like Actions of (2R,6R)-Hydroxynorketamine -- Potential Mechanisms of Antidepressant-like Actions of (2R,6R)-Hydroxynorketamine -- Conclusion -- References -- Predictable Biomarkers for Rapid-Acting Antidepressant Response to Ketamine -- Introduction -- Brain-Derived Neurotrophic Factor -- Shank3 -- Dissociation -- Inflammatory Markers, D-Serine, and Vitamin B12 -- Body Mass Index -- Kynurenine Pathway -- Gamma Power -- Neuroimaging -- Structural and Functional Connectivity -- Sleep -- Cognition -- Conclusion -- References -- Nitrous Oxide: An Old Compound with Emerging Psychotropic Properties -- Brief Medical History of Nitrous Oxide -- Current Medical Applications of Nitrous Oxide -- Nitrous Oxide as an Antidepressant -- Putative Mechanisms of Nitrous Oxide as an Antidepressant -- Administration of Nitrous Oxide -- Dosing of Nitrous Oxide in Depression -- Administration of Nitrous Oxide in Depression -- Nitrous Oxide Abuse Potential -- Nitrous Oxide Compared to Ketamine -- Future Directions -- References.
Novel AMPA Receptor Potentiators TAK-137 and TAK-653 as Potential Rapid-Acting Antidepressants -- Introduction -- Establishment of a Novel Drug Screening Strategy for AMPA-R Potentiators -- Characterization of AMPA-R Potentiators Containing a Dihydropyridothiadiazine 2,2-Dioxide Skeleton with a Different Agonistic Effect -- Discovery and Characterization of TAK-137 -- In Vitro Characterization of TAK-137 Using LY451646 as a Control -- Potent Procognitive Effects and Lower Bell-Shaped Response and Seizure Risks with TAK-137 -- Antidepressant-Like Activity of TAK-137 in Rodents -- Discovery and Characterization of TAK-653 -- Antidepressant-like Activity of TAK-653 in Rodents -- Pharmacokinetic Properties of TAK-653 After Single and Multiple Rising Doses in Healthy Volunteers -- Conclusions -- References -- AMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants -- Introduction -- AMPA Receptors -- AMPA Receptors in Depression -- Effects of Antidepressant Treatments on AMPA Receptors -- History of AMPA Receptor Potentiators -- AMPAR Potentiators as Antidepressants -- Intracellular Signaling of AMPA Receptor Potentiators -- Conclusion -- References -- mGlu2/3 Receptor Antagonists as Rapid-Acting Antidepressants -- Introduction -- mGlu2/3 Receptors: Molecular Properties, Functions, and Roles in Psychiatric Disorders -- Antidepressant Profiles of mGlu2/3 Receptor Antagonists in Rodent Models -- Antidepressant Effects of Stimulation of mGlu2/3 and/or mGlu2 Receptors -- Mechanisms Underlying the Antidepressant Effects of mGlu2/3 Receptor Antagonists -- Synaptic Mechanisms of the Antidepressant Effects of mGlu2/3 Receptor Antagonists -- Role of Monoaminergic Systems in the Antidepressant Actions of mGlu2/3 Receptor Antagonists -- Conclusions -- References. Antidepressant Effects of the Muscarinic Receptor Antagonist Scopolamine: Clinical and Preclinical Review -- Muscarinic Cholinergic Antagonists in the Treatment of Mood Disorders -- Rapid Antidepressant Response to Scopolamine -- Adverse Effects -- Onset and Duration of Scopolamine's Clinical Antidepressant Effects -- Limitations of the Extant Data -- Other Clinical Studies Using Repeated Scopolamine Administrations in Depression -- Advancing Scopolamine Through Reverse Translation -- Scopolamine in Preclinical Models -- Identifying a More Selective Antimuscarinic Antidepressant -- Summary -- Financial Disclosures -- References -- Index. |
| Record Nr. | UNINA-9910506387603321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Trials for Cerebellar Ataxias [[electronic resource] ] : From Cellular Models to Human Therapies / / edited by Bing-wen Soong, Mario Manto, Alexis Brice, Stefan M. Pulst
| Trials for Cerebellar Ataxias [[electronic resource] ] : From Cellular Models to Human Therapies / / edited by Bing-wen Soong, Mario Manto, Alexis Brice, Stefan M. Pulst |
| Autore | Soong Bing-wen |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (716 pages) |
| Disciplina | 616.842 |
| Altri autori (Persone) |
MantoMario
BriceAlexis PulstStefan-M |
| Collana | Contemporary Clinical Neuroscience |
| Soggetto topico |
Neurosciences
Neurology Pharmaceutical chemistry Cognitive neuroscience Neuroscience Pharmaceutics Cognitive Neuroscience |
| Soggetto non controllato |
Internal Medicine
Medical |
| ISBN | 3-031-24345-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I: Basic Science of Cerebellum and Ataxias -- Functional anatomy of the cerebellum -- Cerebellar physiology -- Cerebellar biochemistry/pharmacology -- Genetics of dominant ataxias -- Autosomal and X-linked degenerative ataxias: from genetics to promising therapeutics -- Seeking therapies for Spinocerebellar Ataxia: from gene silencing to systems-based approaches -- Ion Channel Genes and Ataxia -- Part II: Biomarkers and tools of trials -- How to Design a Therapeutic Trial in SCAs -- Therapy development for spinocerebellar ataxia: Rating Scales and Biomarkers -- Clinical rating scales for ataxia -- Scale for Ocular motor Disorders in Ataxia (SODA): Procedures and Basic Understanding -- Cerebellar learning in the prism adaptation task -- Blood and CSF biomarkers in autosomal dominant cerebellar ataxias -- Part III: Autosomal Dominant Cerebellar Ataxias -- Riluzole in progressive cerebellar ataxias -- ASOs against ATXN2 in preclinical and phase 1 trials -- Antisense oligonucleotide therapy against SCA3 -- Spinocerebellar ataxia type 7: From mechanistic pathways to therapeutic opportunities -- Experimental neurotransplantation for cerebellar ataxias -- Development of mesenchymal stem cells therapy for the treatment of polyglutamine SCA: from bench to bedside -- Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia -- Cerebellar Transcranial Magnetic Stimulation in Cerebellar Ataxias -- Physical therapy in Cerebellar Ataxia -- Part IV: Autosomal Recessive Cerebellar Ataxias -- Recent advances on therapeutic approaches for Friedreich’s Ataxia -- Therapeutic use of interferon gamma in Friedreich ataxia -- Metabolic treatments of cerebellar ataxia -- Clinical Trials in Fragile X-Associated Tremor/Ataxia Syndrome -- Part V: Sporadic Ataxias -- Therapeutic strategies in immune-mediated cerebellar ataxias -- Coenzyme Q10 in MSA -- State of the Art and History of Therapeutics in Ataxias. |
| Record Nr. | UNINA-9910728385703321 |
Soong Bing-wen
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
